Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
16
01
2020
accepted:
03
04
2020
pubmed:
11
4
2020
medline:
22
6
2021
entrez:
11
4
2020
Statut:
ppublish
Résumé
Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treated with ICB; 20 who received TBP (TBP cohort) and 44 who stopped ICB at initial progression (non-TBP cohort). The TBP cohort received ICB for a median of 4.7 months after initial progression and delayed subsequent treatment by a median of 6.6 months. Despite receiving more prior lines of therapy, the TBP cohort achieved longer progression-free survival with post-ICB treatment (median, 17.5 months vs. 6.1 months, p = .035) and longer time-to-subsequent treatment failure, defined as time from initial ICB progression to failure of subsequent treatment (median, 34.6 months vs. 9.9 months, p = .003). With the limitations of a retrospective study, these results support the clinical benefit of TBP with ICB for selected patients.
Identifiants
pubmed: 32275786
doi: 10.1634/theoncologist.2020-0040
pmc: PMC7288660
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e993-e997Informations de copyright
© AlphaMed Press 2020.
Références
J Clin Oncol. 2018 May 10;36(14):1428-1439
pubmed: 29584546
Blood. 2017 May 4;129(18):2471-2478
pubmed: 28270452
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Blood. 2016 Nov 24;128(21):2489-2496
pubmed: 27574190
Blood. 2017 Jul 13;130(2):221-228
pubmed: 28468799
J Clin Oncol. 2017 Jul 1;35(19):2125-2132
pubmed: 28441111
Ann Oncol. 2017 Jul 1;28(7):1436-1447
pubmed: 28379322
Eur J Cancer. 2018 Mar;91:136-144
pubmed: 29360605